- Aug 14, 2013
- 2,455
- Tinnitus Since
- Resolved since 2016
- Cause of Tinnitus
- Unknown (medication, head injury)
Since about a year and a half, the involvement of certain Kv7-channels in relation to the induction of tinnitus, has been closely followed by a large number of members of TinnitusTalk. Retigabine is known to target this set of Kv-channels (with the addition of Kv7.4/5). The potential for Retigabine to prevent the development of tinnitus (following noise exposure) was indicated in a 2013-article by the well known tinnitus researcher, Prof. Tzounopoulos:
http://www.dailymail.co.uk/health/a...TINNITUS-reduces-hyperactivity-cells-ear.html
Towards the end of 2014, and as part of [USERGROUP=11]@Team Trobalt[/USERGROUP], I got in touch with Prof. Tzounopoulos to learn more about the mechanism-of-action of Retigabine (in relation to tinnitus). From that correspondence, I came to know about a novel Kv-channel opener with increased selectivity and greater potency than Retigabine - the reply can be seen here:
https://www.tinnitustalk.com/thread...-—-petition-to-the-ata.6896/page-4#post-80103
The new compound mentioned in that correspondence turned out to be SF0034. As part of the on-going efforts of Team Trobalt, I learnt during the spring of 2015 that, yet another development was underway. I therefore also knew - as with what turned out to be SF0034 - that there was yet another development to unfold at some point in the future. That development came to the surface, when, Monday this week, I learnt that the manuscript pertaining to yet another and yet more potent Kv-channel opener had been released. The name of the lead compound is RL648_81.
Before any of the news articles were published, I managed to briefly get feedback from one of the co-authors of the paper - in particular to learn if tinnitus would be in scope of a future clinical trial. The feedback was: "We are certainly planning for a tinnitus development, but we are still pursuing preclinical studies..."
Given the disappointing news from the QUIET-1 study of Autifony Thereapeutics in 2015, I believe that there is yet again room to be at least cautiously optimistic for a future treatment of tinnitus.
Read more about the development via the link below.
http://www.dailymail.co.uk/health/a...TINNITUS-reduces-hyperactivity-cells-ear.html
Towards the end of 2014, and as part of [USERGROUP=11]@Team Trobalt[/USERGROUP], I got in touch with Prof. Tzounopoulos to learn more about the mechanism-of-action of Retigabine (in relation to tinnitus). From that correspondence, I came to know about a novel Kv-channel opener with increased selectivity and greater potency than Retigabine - the reply can be seen here:
https://www.tinnitustalk.com/thread...-—-petition-to-the-ata.6896/page-4#post-80103
The new compound mentioned in that correspondence turned out to be SF0034. As part of the on-going efforts of Team Trobalt, I learnt during the spring of 2015 that, yet another development was underway. I therefore also knew - as with what turned out to be SF0034 - that there was yet another development to unfold at some point in the future. That development came to the surface, when, Monday this week, I learnt that the manuscript pertaining to yet another and yet more potent Kv-channel opener had been released. The name of the lead compound is RL648_81.
Before any of the news articles were published, I managed to briefly get feedback from one of the co-authors of the paper - in particular to learn if tinnitus would be in scope of a future clinical trial. The feedback was: "We are certainly planning for a tinnitus development, but we are still pursuing preclinical studies..."
Given the disappointing news from the QUIET-1 study of Autifony Thereapeutics in 2015, I believe that there is yet again room to be at least cautiously optimistic for a future treatment of tinnitus.
Read more about the development via the link below.